Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Double-Masked, Randomized, Vehicle-Controlled Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease

NCT05238597 is registered in ClinicalTrials.gov with Aramis Biosciences, Inc. as lead sponsor.

NCT NCT05238597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05238597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Double-Masked, Randomized, Vehicle-Controlled Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease
Lead sponsor
Aramis Biosciences, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 25, 2022
Completion date
January 24, 2023
Enrollment
207 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye disease